Product Description
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Germany | Portugal | Spain
Approved Indications: None
Known Adverse Events: None
Company: Venter Pharma S.L.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Lactose Intolerance
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
VPH-GXL-2022-511 | P1 |
Unknown Status |
Healthy Volunteers |
2023-06-30 |
|
2015-001181-26 | P4 |
Active, not recruiting |
Lactose Intolerance |
2015-09-07 |